View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Carole Braudeau
  • Carole Braudeau

Credit Morning 12/19/2025

Coty announces sale of remaining 25.8% stake in Wella|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 19/12/2025

Coty annonce la cession de sa participation résiduelle de 25,8% dans Wella|

Felix Fischer
  • Felix Fischer

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: AMS Osram

Felix Fischer ... (+5)
  • Felix Fischer
  • Haidje Rustau
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Liberty Global, Fedrigoni, Oriflame, Synthomer, AMS Osram, Tele Columbus

 PRESS RELEASE

DBV Technologies Announces Positive Topline Results from Phase 3 VITES...

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15% 46.6% of children treated with the VIASKIN® Peanut patch met response criteria a...

 PRESS RELEASE

DBV Technologies annonce des résultats préliminaires positifs dans l’é...

DBV Technologies annonce des résultats préliminaires positifs dans l’étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques à l’arachide Châtillon, France, le 16 décembre 2025 DBV Technologies annonce des résultats préliminaires positifs dans l’étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques à l’arachide VITESSE a atteint son critère d’évaluation principal : la limite inférieure de l’intervalle de confiance à 95 % (IC) à savoir la différence entre les taux de réponse des groupes actif et pl...

Carole Braudeau
  • Carole Braudeau

Credit Morning 12/08/2025

Worldline plans to sell PaymentIQ for € 160m|BNP sells 25% stake in AG Insurance to Ageas; Cardif builds up stake in Ageas to 22.5%|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 08/12/2025

Worldline compte céder la plateforme PaymentIQ pour 160 m EUR|BNP cède à Ageas sa participation de 25% dans AG ; Cardif se renforce au capital d’Ageas à 22.5%.|

 PRESS RELEASE

Information Regarding the Total Number of Voting Rights and Total Numb...

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025 Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345  Date  Total number of shares Total number of voting rights11/30/2025 200,777,718  Total gross of voting rights: 200,777,718  Total net* of voting rights: 200,667,869  * Net total = total number of voting rights at...

 PRESS RELEASE

Information relative au nombre total des droits de vote et d’actions c...

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2025 Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2025 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE Euronext Paris Code ISIN : FR 0010417345  Date  Nombre totald’actionscomposant le capital socialNombre totalde droits de vote30/11/2025  200.777.718  Total brut des droits de vote : 200.777.718  Total net* des droits de vote : 200.667.869  *Total net = nombre t...

Pierre FerraguÊ
  • Pierre FerraguÊ

AI bubble?, Autos, PC cycle, Nokia CMD, Palo Alto, and more. Our weekl...

As always, during earnings season, we wrap-up what happened in the previous week. For our main takes summarized on a single slide, and a few words on each of the names we followed last week, follow the link.

Felix Fischer
  • Felix Fischer

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: AMS Osram

Felix Fischer ... (+6)
  • Felix Fischer
  • Haidje Rustau
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Eircom, EVOCA, Altice France (SFR), Stada, TGS ASA, EnQuest Plc, Crown Holdings, Alain Afflelou, Manuchar, Asmodee, Novelis, Arxada, Ahlstrom, AMS Osram, Ardagh Metal Beverage Packaging, Odigeo, Motel One

Felix Fischer ... (+2)
  • Felix Fischer
  • Trung Nguyen

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: AMS Osram, Nissan Motor

Felix Fischer ... (+7)
  • Felix Fischer
  • Haidje Rustau
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora
  • Trung Nguyen

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Digi Communications, Vallourec, EVOCA, AMS Osram, Rekeep, Arxada, Manuchar, Nissan Motor, Motel One, Versuni, Grunenthal, Mooney (formerly SisalPay), Cerba

 PRESS RELEASE

DBV Technologies Announces Last Patient Visit Completed in VITESSE Pha...

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Châtillon, France, November 11, 2025 DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Company remains on track for VITESSE topline data in Q4 of this year DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that the l...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch